Find Funding Opportunities

Find Funding Opportunities

Returning 1358 results

Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 Clinical Trial Not Allowed)

RFA
Friday, June 14, 2019
Thursday, August 15, 2019
R01
RFA-NS-19-039

Funding Opportunity Purpose

(Reissue of RFA-NS-16-021, PAR-18-413) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or cerebellum. Though most commonly extending out from the periventricular surfaces, it may also occur in subcortical white matter. Diffuse white matter disease is typically detected in clinical settings as hyperintensity on magnetic resonance imaging (MRI) or signal loss on computed tomography x-ray (CT) scan; diffuse white matter disease can be detected histologically as well, for example in human pathology and in studies using animal models. Despite the prevalence and potential significance of white matter disease for cerebrovascular disease etiology and cognitive outcomes, much remains to be learned about the cellular and molecular causes, regional vulnerability, and progression over time. The physiological consequences of diffuse white matter disease on local axon and neural circuit function are almost completely unknown. The purpose of this FOA is to address some of the many gaps in knowledge of the biologic mechanisms of the commonly occurring, cerebrovascular disease and age-related diffuse white matter disease at the molecular, cellular, tissue and brain circuit level. The ultimate goal of this fundamental research is to inform future efforts to reduce the burden of illness due to age-related vascular contributions to cognitive impairment and dementia.

Research Program Award (R35 Clinical Trial Optional)

RFA
Wednesday, May 29, 2019
Clinical Trials Research
Wednesday, July 31, 2019
R35
RFA-NS-19-037

Funding Opportunity Purpose

Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program. Other anticipated benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, thereby allowing investigators to spend more time conducting and overseeing research; and More time for PDs/PIsto mentor junior scientists. Eligibility to apply through this FOA is limited to investigators who currently have at least one active NINDS R01 or R01 equivalent grant (defined here as R00, R01, R37, R56, DP1 or DP2 awards), and who have had an active R01 equivalent grant from NINDS in each of the past 5 years, with no more than one of those years in a no cost extension.

HEAL Initiative: Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers (U24 Clinical Trial Not Allowed)

RFA
Thursday, April 18, 2019
Tuesday, June 4, 2019
U24
RFA-NS-19-036

Funding Opportunity Purpose

(RFA-NS-19-025 is being reissued to accommodate an additional receipt date). The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (hubs) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites (spokes). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Data Coordinating Center (RFA-NS-18-035). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

Late-Stage Implementation Research Addressing Hypertension in Low- and Middle-Income Countries: Scaling Up Proven-Effective Interventions (UG3/UH3 Clinical Trial Optional)

RFA
Thursday, April 11, 2019
Tuesday, July 9, 2019
UG3/UH3
RFA-HL-20-005

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) seeks grant applications to optimally and sustainably address late-stage implementation research questions to address scaling up evidence-based interventions at the population level for prevention and management of hypertension in low- and middle-income countries and small island developing states. For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical and public health and community-based settings and maximize the positive impact on population health. Each awarded project is to conduct late-stage implementation research in one of six geographical regions (e.g., East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa). As a group, awardees will constitute a research alliance for hypertension implementation science research in low-resource settings with capabilities for addressing scale-up of evidence-based interventions at the population level for the prevention and management of hypertension. This program is not intended to support research that can be conducted primarily in and/or by the United States or other high-income institutions that do not meet eligibility criteria. This FOA uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement mechanism. Awards made under this FOA will initially support a two-year milestone-driven needs assessment and planning, with possible transition to an implementation (UH3) phase of up to 4 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase.

Accelerating Medicine Partnership in Parkinsons disease (AMP PD) unbiased proteomics biofluid analysis (U01 Clinical Trials Not Allowed)

RFA
Friday, April 5, 2019
Thursday, May 30, 2019
U01
RFA-NS-19-028

Funding Opportunity Purpose

The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from the Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data and workflows generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. The proteomics analysis will be staged to include identification of pre-analytical variables, that will inform the optimal handling of 4,500 CSF and plasma samples.

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24 Clinical Trial Not Allowed)

RFA
Wednesday, April 3, 2019
Thursday, July 25, 2019
U24
RFA-DA-20-004

Funding Opportunity Purpose

NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a limited competition Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for a Coordinating Center in service of a nationwide, multisite, multi-modal, longitudinal cohort study to prospectively examine brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis, Informatics and Resource Center (U24 Clinical Trial Not Allowed)

RFA
Wednesday, April 3, 2019
Thursday, July 25, 2019
U24
RFA-DA-20-003

Funding Opportunity Purpose

NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for a Data Analysis, Informatics, and Resource center to oversee and manage the standardization of data collection procedures, provide technical support, ensure quality control, perform integrative data analysis, and coordinate data storage and data sharing activities for a nationwide, multisite, multi-modal, longitudinal cohort study that prospectively examines brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed)

RFA
Wednesday, April 3, 2019
Thursday, July 25, 2019
U01
RFA-DA-20-002

Funding Opportunity Purpose

NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for research project sites in service of a nationwide, multisite, multi-modal, longitudinal cohort study to prospectively examine brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

Medical Rehabilitation Research Resource (P2C Clinical Trial Optional)

RFA
Wednesday, March 13, 2019
Friday, June 28, 2019
RFA-HD-20-004

Funding Opportunity Purpose

This is the renewal of a Funding Opportunity Announcement (FOA), issued by NICHD, NINDS, NIBIB, NIDCD, and NINR, National Institutes of Health, to invite grant applications from institutions/organizations that propose to build a research infrastructure center to promote external collaboration with the medical rehabilitation community. The aim of this FOA is to create a national network of research centers that provide access to collateral expertise in biomedical, behavioral, engineering, and/or psychosocial fields that are particularly relevant to medical rehabilitation research and the needs of people with chronic physical disabilities. Specifically, the NIH is interested in addressing gaps in the rehabilitation research portfolio and is particularly interested in the following high-priority areas: pediatric rehabilitation; personalized medicine approaches; family, caregiver, and community support; implementation and dissemination research; clinical trial design and combinatorial therapies; strategies to explore and validate combination therapies; and, technology to track real-world outcomes.

Administrative Supplement for Research on Bioethical Issues

PA
Tuesday, March 12, 2019
Tuesday, May 14, 2019
333
PA-19-217

Funding Opportunity Purpose

The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support research on bioethical issues to develop and evidence base that may inform future policy directions. Applicants may propose to supplement parent awards focused on bioethics or to add a component related to bioethics to a parent award in which bioethics was not the focus. Areas of high priority research include, but are not limited to, the bioethical, legal, and societal implications of the following: New and emerging technology development and use; clinical and non-clinical data sharing; precision and personalized medicine; research privacy and security; learning healthcare systems; crowdsourcing; participant-driven research and consumer generated data; patient/participant representation in research oversight; special and vulnerable population research; individual or community health, treatment, and/or research disparities; issues related to the inclusion of Tribal and American Indian/Alaska Native populations; current and emerging regulatory environments; innovative study design, conduct, management, and oversight; international research; research on stigmatized conditions; historical analyses of bioethics issues; and novel approaches for enhancing bioethics infrastructure and training.

Pages